Home > Cardiology > Clopidogrel cessation after atrial-septal-defect repair doesn’t boost migraine risk

Clopidogrel cessation after atrial-septal-defect repair doesn’t boost migraine risk


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Cardiology
Reuters Health - 02/10/2020 - Withdrawal of clopidogrel from patients undergoing dual antiplatelet therapy following transcatheter atrial-septal defect (ASD) closure does not increase the risk of new-onset migraine attacks, according to new research. "It is well known that adding clopidogrel to aspirin for three months after transcatheter ASD closure results in a lower incidence of new-onset migraine attacks," Dr. Josep Rodes-Cabau of Laval University, in Quebec City, Canada, explained in an email to Reuters Health. "Our current study," he said, "showed that migraine attacks post-ASD closure improved/resolved spontaneously within six to 12 months in most patients. No significant rebound effect was observed after clopidogrel cessation at three months." In a paper in JAMA Cardiology, Dr. Rodes-Cabau and colleagues note that about 15% of patients present with new-onset migraine headaches within days or weeks following ASD. In the CANOA trial, which includ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on